Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study

BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor that is being investigated for inflammatory bowel disease. AIMS: This 48‐week open‐label extension study primarily investigated long‐term safety of tofacitinib 5 and 10 mg b.d. and secondarily investigated efficacy as maintena...

Descripción completa

Detalles Bibliográficos
Autores principales: Panés, Julián, D’Haens, Geert R., Higgins, Peter D. R., Mele, Linda, Moscariello, Michele, Chan, Gary, Wang, Wenjin, Niezychowski, Wojciech, Su, Chinyu, Maller, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Safety of Tofacitinib in Crohn's Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646954/
https://www.ncbi.nlm.nih.gov/pubmed/30663107
http://dx.doi.org/10.1111/apt.15072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6646954/
https://www.ncbi.nlm.nih.gov/pubmed/30663107
http://dx.doi.org/10.1111/apt.15072

Ejemplares similares